RNA Formulation Videos

  1. Scale Up And Manufacturing Of RNA-LNPs For A COVID-19 Vaccine 4/13/2022

    Dr. Jason Coleman, Clinical Application Scientist Lead with Precision NanoSystems, presents on an overview of the development and scale-up activities needed to progress this saRNA vaccine to the clinic.

  2. Achieving mRNA-LNP Delivery Beyond The Liver 11/28/2022

    In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, discuss which ongoing industry efforts to improve LNPs and the RNA/mRNA cargo they're watching closely that could help the RNA industry move beyond hepatic delivery.

  3. How To Manufacture LNPs On The Nova Benchtop System 4/18/2024

    Walk step-by-step instructions through how you can set up the Nova Benchtop System and make your first LNPs.

  4. Nanoparticle Enabled Formulation And Drug Delivery Solutions

    Discover how revolutionary and environmentally sustainable nanoparticle technologies coupled with innovative formulation approaches can address drug solubility issues and add value for patients.

  5. RNA-LNP Manufacturing Technology Delivering Transformative Medicines 10/13/2022

    NxGen™ microfluidic technology enables controlled and precise assembly of high-quality, uniform LNPs, ensuring reproducible scale-up of RNA-LNPs while maximizing drug loading and particle quality.

  6. The Next Frontier In mRNA: Modular Manufacturing For Scalable RNA-LNP Therapies 1/29/2025

    Explore constructing a modular RNA-LNP GMP facility using Cytiva's FlexFactory™ process train in a KUBio™ environment to scale RNA-LNP therapies.

  7. Addressing Industry Challenges In mRNA Product Commercialization

    While the speed of production and flexibility of mRNA are appealing, several industry challenges must still be addressed to realize the full potential and further expand its use.

  8. The Scientific Underpinnings Of mRNA/LNPs 11/28/2022

    In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their thoughts on the scientific-research and CMC-related reasons that have made the lipid nanoparticle the “darling” of the delivery world for mRNA/RNA products today.

  9. The Pre-IND "Diaries": What Can mRNA Makers Expect From Early FDA Engagement? 5/10/2024

    Nutcracker Therapeutics’ Oreanna Thomas shares her takeaways from a pre-IND meeting for one of the company’s mRNA therapeutic candidates.

  10. The State of the Linear mRNA Supply Chain—In Brief

    In this clip, Sanofi’s Greg Troiano kickstarts our discussion on some of the advances he’s seen in the supply chain for linear mRNA-LNP products, both in terms of supply availability and supplier capability.